MarketPeel
Insider Trading Intelligence
Pricing
…
MS

Mcdavid Stilwell

CHRS
CHIEF FINANCIAL OFFICER · COHERUS ONCOLOGY, INC. · CIK 0001851389
FILING MIX · LIFETIME62%/38%
BUYS
8
SELLS
5
TOTAL VALUE
$291.7K
COMPANIES
1
ACTIVE SINCE
Apr 2021
HOLDINGS NOW
75,305
AVG SELL PX
$7.06
TRADE KIND
SHOWING 13 / 13
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Mcdavid Stilwell, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%+2.53%+0.87%+1.66%+1.66%—
14d2+100.00%+3.43%+1.78%+1.65%+1.65%—
30d2+50.00%+5.76%+4.23%+1.53%+1.53%—
60d2+50.00%-2.60%+4.56%-7.17%-7.17%—
90d2+100.00%-3.41%+5.99%-9.40%-9.40%—
180d2+100.00%-0.54%+4.80%-5.34%-5.34%—
1y2+50.00%-48.57%-11.05%-37.52%-37.52%—
2y2+50.00%-68.60%+2.95%-71.55%-71.55%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CHRS · 75,305 shares · as of Dec 31, 2023
026,06152,12278,182104,24320222023SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
FLOW · 8 buys / 5 sellsCOVERAGE · 11 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Financial Officer
18,440$3.33$61.4K75,305Dec 31, 2023Jan 3, 2024 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
70,000——70,000Jun 13, 2023Jun 15, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Financial Officer
3,457$6.84$23.6K102,252Apr 1, 2023Apr 4, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
40,000——104,243Jan 20, 2023Jan 24, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
80,000——80,000Jan 4, 2023Jan 6, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Financial Officer
5,437$9.87$53.7K64,243Jan 4, 2023Jan 6, 2023 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Financial Officer
3,458$12.85$44.4K69,680Apr 1, 2022Apr 5, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
80,000——80,000Jan 4, 2022Jan 6, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
40,000——73,138Jan 4, 2022Jan 6, 2022 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
SALE
Chief Financial Officer
3,507$16.80$58.9K31,611Oct 15, 2021Oct 19, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASE
Chief Financial Officer
3,700$13.42$49.7K35,118Jun 9, 2021Jun 10, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
20,000——30,000Apr 28, 2021Apr 30, 2021 ↗View →
CHRS
COHERUS ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Apr 28, 2021Apr 30, 2021 ↗View →
Other insiders · CHRS
Loading peer insiders…
About this filer
CIK 0001851389
ROLE
Chief Financial Officer
PRIMARY
CHRS
COMPANIES
1
ACTIVE SINCE
Apr 2021
MARKETPEEL · /INSIDER/0001851389DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback